Solara Active Pharma Sciences Limited — Others, 15-05-2025: Appointment

Solara Active Pharma Sciences Limited has announced a board meeting outcome approving the financial results for the quarter and half-year. The company allotted 1 lakh equity shares under its Employee Stock Option Plan and appointed Ms. Pooja Jaya Kumar as Company Secretary & Compliance Officer. It revised its Insider Trading Code, appointed Ms. Parimala Natarajan as Secretarial Auditor, re-appointed M.K. Suryanarayanan as Cost Auditor, and brought on Grant Thornton Bharat LLP as Internal Auditors for FY26. FY25 consolidated revenues were Rs. 1,292.08 Cr, flat YoY, with gross margin improving to 51.5%, driving EBITDA to Rs. 213.8 Cr from a loss the prior year. Gross debt fell to Rs. 77.6 Cr, with net debt to EBITDA expected to improve post rights issue. The company zeroed USFDA observations across multiple facilities. A carve-out of the CRAMS and Polymers business into “Synthix Global Pharma Solutions Limited” was approved to unlock value and strengthen Solara’s balance sheet by transferring Rs. 20 Cr debt. Q4 saw Rs. 279 Cr revenue, 57.5% gross margin, and 18.3% EBITDA margin, reflecting margin focus despite pricing pressures. Operating costs declined 16% YoY in Q4 and 22% for FY25. FY26 targets 10% revenue and 15-20% EBITDA growth, emphasizing profitability, cost control, working capital optimization, and deleveraging.